Increased glucocorticoid receptor activity and proliferation in metastatic colon cancer

Dan Tian¹, Miao Tian², Gang Han³ & Jin-Long Li³

Metastasis is regarded as the fatal hallmark for colon cancer, but molecular mechanisms responsible for it have remained poorly defined. Glucocorticoid receptor (GR) within the tumor microenvironment mediates the effects of stress hormones which are used in clinics for their inflammation-modulatory and immunosuppressive properties. Further, epigenetic activation of GR promotes tumor heterogeneity and metastasis. Here, we sought to investigate the correlation between GR activation and proliferation and invasion in metastatic colon cancer microenvironment. We used proliferation/invasion assays, western blot, RT-qPCR, immunofluorescence staining and quantitative methylation to study glucocorticoid-GR signaling, including the involvement of CDK1, in human colon adenocarcinoma cell lines HT29 and T84 (a representative metastatic cell line). Nuclear expression levels of GR were significantly upregulated in metastatic T84 cells, and glucocorticoid derivative, dexamethasone (DEX) treatment caused increased proliferation and invasion in T84 cell, compared to HT29 cell. DEX treatment induced CDK1 expression which was accompanied by reduced CDK1 methylation, indicating epigenetic regulation. Depletion of GR suppressed proliferation of metastatic colon carcinoma cells and depletion of CDK1 had similar suppressing effects on proliferation as well as invasion of metastatic cells. Our study suggests that glucocorticoid-GR-CDK1 signaling induces proliferation and invasion of colon cancer cells and therapies involving the use of glucocorticoids need to exercise caution and re-evaluation.

Colorectal cancer (CRC) is one major cancer that results in numerous cancer-related deaths around the world¹-³. The 5-year overall survival of CRC patients differs for patients representing different clinical stages. While the 5-year survival for stage I CRC patients is 93%, it stands at an unacceptable rate of 8% for stage IV patients¹. At present, surgical resection is considered the most effective treatment for CRC, with only a modest benefit afforded by chemotherapy⁴. Despite all the research, CRC survival rates have not improved over past several decades. Therefore, discovery and validation of clinically relevant diagnostic and prognostic markers is urgently needed.

Liver is a frequent and often the first metastatic site for advanced CRC. It is also the exclusive site of metastatic spread in 30–40% of advanced CRC patients. Hematogenous spread of CRC often follows a pattern wherein hepatic metastasis occurs first, followed by the involvement of portal vein in intra-hepatic spread, leading ultimately to systemic circulation, thus, resulting in surgical resection of hepatic metastatic modules as an effective approach to counter metastatic spread and improve overall survival of patients⁵. As would be expected, metastatic CRCs are particularly lethal, with a median survival of eight months when left untreated⁶. However, CRC patients, who have undergone surgery for the resection of hepatic metastases, report much better prognosis, provided that the metastatic spread is not substantially more exhaustive⁷.

Our primary hypothesis for this study was that glucocorticoid-GR signaling promotes cell proliferation in metastatic CRC. We show that treatment of metastatic human colon carcinoma cell line, T84 with dexamethasone (DEX), a potent synthetic glucocorticoid, which is reminiscent of signaling within the tumor microenvironment, led to enhanced proliferation as well as invasion, compared to non-metastatic CRC cell line, HT29. We further show that DEX promoted cell proliferation in T84 by inducing expression of cyclin-dependent kinase 1 (CDK1) expression. CDKs consist of a family of protein kinases driving the major events of cell cycle in eukaryotic cells⁸, and it has been reported that de-regulated CDKs not only induce rapid tumor growth but also support...
proliferation of cancer cells. In view of our findings, we advocate due caution while including glucocorticoids in the treatment strategy for CRC patients, particularly the CRC patients with metastatic and advanced disease.

**Materials and Methods**

**Cell culture.** HT29 and T84, the human colon carcinoma cell lines, were obtained from ATCC, USA, and cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum. The cells were grown in a humidified incubator at 37°C and 5% CO₂.

**Reagents.** DEX was from Sigma-Aldrich (Shanghai, China). CDK1, β-actin, p65, and GR antibodies were from Santa Cruz Biotechnology (TX, USA). siRNAs were designed and synthesized by IDT DNA (USA).

**Western blot.** We used nuclear extraction kit (Millipore, China) to prepare the nuclear and cytosolic cell extracts. 1× SDS loading buffer was added to the proteins, and SDS electrophoresis was performed by resolving samples on SDS–10% PAGE gels. This was followed by transfer onto PVDF membranes (Bio-Rad, China) and blocking of membranes using 5% nonfat milk powder in PBST, and finally overnight incubation with primary antibodies at 4°C and an hour long incubation with appropriate secondary antibodies with extensive washings in between. We used β-actin as loading control. Immun-Star HRP Substrate (Bio-Rad, China) was used for the visualization of protein bands on autoradiograms.

**Immunofluorescence (IF) staining.** Cells were fixed using 4% paraformaldehyde in PBS, and permeabilized for 10 minutes, using 0.5% Triton X-100 in PBS. This was followed by washing and overnight incubation at 4°C with appropriate antibodies; washing to remove excess antibodies and incubation with fluorophore-conjugated secondary antibody (Alexa Fluor 488 goat anti-rabbit IgG) for 1 hour at room temperature. Finally, cells were counterstained with 4′,6-diamidino-2-phenylindole DAPI (Invitrogen, China) and visualized using a fluorescence microscope (Olympus, Japan).

**Preparation of total RNAs.** Total RNA content of cells was extracted by directly adding Trizol-LS reagent (Invitrogen, China) to the plates and following manufacturer's protocol. We collected aqueous phase after the addition of chloroform and added ethanol, followed by centrifugation to precipitate RNAs out. RNA pellet was dissolved in 10 μL of nuclease-free water and the purity and concentration measured on a NanoDrop instrument (ThermoScientific, China).

**Quantitative RT-PCR.** For quantitative estimation of mRNAs, we used oligo-dT primers for total cDNA synthesis, using the Superscript II Reverse Transcription kit (Invitrogen, China), and used ABI7300 machine (Applied Biosystems, China). mRNA levels were determined with relative to GAPDH expression using the SYBR Green PCR kit (Qiagen, China), respectively. Fold change was determined by the method of cycle...
threshold (CT) in the formula of $2^{-\Delta \Delta CT}$. GAPDH forward, 5'-CTCCCGCTTCGCTCTCTG-3', GAPDH reverse, 5'-CTGGCGACGCAAAAGAAG-3'; CDK1 forward, 5'-AAAGCCTAGGGCAGAGTGGT-3'; CDK1 reverse, 5'-GGTTTGTAGAACTGGTGCAA-3'.

Chromatin Immunoprecipitation (ChIP). ChIP was performed, exactly as described previously. Fold enrichment was calculated with the method of cycle threshold in the formula of $2^{-\Delta \Delta CT}$. The primers (forward/reverse) used for the amplicon to CDK1 promoter were 5'-AAAGAAGAACGGAGCAACA-3'/5'-GCTAGAGCGAAAGAAAGA-3'. Control primers (forward/reverse) for a non-binding site (a human DNA alpha satellite) were 5'-TCTCAGAATCTTCCTTTTGATGTG-3'/5'-CCAGTTGCAGATCCTACAAAGA-3'.

Methylation quantitation. We determined the levels of methylation in colon carcinoma cells using FFPE Bisulfite conversion kit from Active Motif (Shanghai, China). Manufacturer's protocol was used without any modifications and primers were designed, using established methodology.

Cell proliferation assay. MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazoliumbr-omide] - based assay was performed to study cell proliferation, as previously described. Cells were seeded into 96-well plates (5,000 cells/well in 200 µL medium) for 24 hr prior to the assay. Once the assay was complete, 20 µL of 5 mg/ml MTT (Sigma, China) solution was added to every single well and the plates incubated for another 4 hr in the cell culture incubator. This was followed by replacement of liquid with 150 µL DMSO (Sigma-, China). Finally, OD was determined at 490 nm using multi-microplate test system (Victor3, MA, USA).

Cell invasion assay. Cell invasion was studied using cell invasion kit purchased from R&D Systems (Shanghai, China) which contained 96-well boyden chamber with a polyethylene terephthalate membrane pre-coated with Basement Membrane Extract (BME) at medium density, to investigate cell invasion in vitro. Treated or control cells were placed in the top chamber and those that invaded through the BME and filter pores to the bottom of filter were quantified using a cell dissociation / calcein AM solution.
**Results**

**GR is constitutively activated in metastatic colon carcinoma cell line.** The transcription factor, GR, is expressed in almost all types of cells within the human body. Upon ligand glucocorticoid binding, the glucocorticoid-GR (hormone-receptor) complex translocates to nucleus and then acts on target gene promoter resulting in modulation of gene transcription. In order to determine whether GR is activated in colon cancer, we performed western blotting analysis on extracts (nuclear and cytosolic) prepared from HT29 or T84 cell line. As shown in Fig. 1A, we did not notice any difference in GR in protein abundance between these cell lines. However, GR levels were remarkably increased in the nuclear extracts in T84 cells, compared to HT29 cells (Fig. 1B). Moreover, the increased nuclear localization in T84 cells was also visualized by immunofluorescence staining (Fig. 1C). Taken together, these results suggest that GR is constitutively activated in metastatic colon carcinoma cells at a higher rate than the non-metastatic colon carcinoma cells.

**Glucocorticoid-GR signaling promotes metastatic colon carcinoma proliferation.** HT29 or the metastatic cells T84 were exposed to DEX (1 μM) for 24 hr or the DMSO (control). MTT proliferation assay was then performed and the results show that DEX-treatment caused a significant increase in cancer cell proliferation in T84 cells, compared to HT29 cells (Fig. 2A). Then, we performed invasion assay and observed that, similar to proliferation, DEX-treatment resulted in more invasion of T84 cells, compared to HT29 cells (Fig. 2B). To verify...
that these observed results were an outcome of glucocorticoid-GR interaction, we silenced GR in T84 cells, using siRNA against GR. The silencing was very efficient (Fig. 2C) and the silencing of GR, followed by DEX treatment, resulted in much reduced proliferation (Fig. 2D) verifying an important role of GR in proliferation of metastatic cells T84. These results suggested that glucocorticoids stimulate metastatic colon cancer cell proliferation by activating GR.

**Glucocorticoid-GR signaling induces gene expression of CDK1 in metastatic colon carcinoma.**
Cancer proliferation and invasion is predominantly caused by dysregulation of CDKs15–18. In order to evaluate whether glucocorticoid-GR signaling involves regulation through CDK1, particularly in metastatic colon cancer cells, we first used ChIP assay to determine the occupancy of GR at CDK1 gene promoter (Fig. 3A,B). p65 was used as a control. Furthermore, we found that DEX exposure of T84 cells resulted in an increase in CDK1 expression at protein (Fig. 3C) and mRNA levels (Fig. 3D). Epigenetic regulation, such as methylation, also plays a role in eventual expression of genes19. Therefore, we also checked for the methylation of CDK1 in T84 cells treated with control or DEX. DEX-treated cells had significantly reduced methylation and this can explain the increased expression of CDK1. These results suggest that glucocorticoid-GR signaling stimulates CDK1 expression in
metastatic colon carcinoma. There seems to be epigenetic mechanisms involved as well, which need to be studied further.

**CDK1 stimulates proliferation and invasion of metastatic colon carcinoma cells.** Human metastatic colon cell line T84 were transiently transfected with CDK1 siRNA for 48 hr with non-specific siRNAs as the controls. The depletion of CDKI was confirmed by western blot (Fig. 4A). MTT proliferation assay showed that inhibition of CDK1 suppressed cancer cell proliferation (Fig. 4B) as well as invasion (Fig. 4C), in a time-dependent manner. These results suggest that glucocorticoid-GR signaling stimulated-proliferation and invasion is mediated by increased expression of CDK1 gene in metastatic colon carcinoma.

**Discussion**

CRC is one of the major human cancers that is responsible for numerous deaths throughout the world. Despite the research efforts over past several decades, there has been no major breakthrough to substantially improve the way CRC patients are treated in the hospitals. As a result, there is urgent need to discover novel diagnostic and prognostic markers of CRC for the ultimate goal of improving the outcome of CRC patients. As a step in this direction, here we show that glucocorticoid-GR signaling plays an important role in proliferation of metastatic human colon carcinoma cells, at least in part, by inducing **CDK1** gene expression (Fig. 5).

Cancer heterogeneity poses as one of the major blockades for treatment of a variety of metastatic cancers including colon cancer. It has been reported that levels of stress hormones are elevated in patients with metastatic cancer including breast cancer, compared to those with age-matched healthy counterparts or patients without metastases. In addition, patients of advanced breast cancer with deregulated cortisol rhythms usually have shorter survival. Very recently, a study by Obradovic et al. demonstrated that the increase of stress hormones during breast cancer progression leads to the activation of the glucocorticoid receptor (GR) at distant metastatic sites, increased colonization but decreased survival. We found that the stress hormone pathway is an effective inducer of proliferation of metastatic colon carcinoma. Furthermore, our data have demonstrated that inhibition of GR abolished glucocorticoid-mediated upregulation of cancer cell proliferation and invasion. As a result, our results support that caution is needed when administering corticosteroids to cancer patients, as proposed, and inhibition of GR may actually be helpful for chemotherapy of metastatic colon cancer.

CDKs regulate the cell cycle by interacting with cyclins. CDK1 is the principal CDK that functions to promote G2-M transition, and regulates G1 progression and the G1-S transition within the cell cycle. Cell proliferation, one of the hallmarks of malignant tumors, is often promoted by dysregulation of CDK activity, and change in CDK expression and/or activity is frequently observed in many human cancers. Other than cell-cycle regulation, CDK1 is involved in apoptosis by caspase phosphorylation including the inhibitory phosphorylation of caspase-8. To this end, Zhang and colleagues have demonstrated that targeting CDK1 is an effective strategy to enhance the efficacy of MEK inhibition in mutant **BRAF** colorectal cancer cell lines and tumor xenographs, consistent with a previous report on the relevance of CDK1 as a therapeutic target in human colorectal cancers. In the current study, we have shown that depletion of either GR or CDK1 halted proliferation of metastatic colon carcinoma. These results further support the high relevance of GR or CDK1 as a therapeutic target in human colorectal cancer, especially for distant metastasis.

In conclusion, we identify glucocorticoid-GR-CDK1 signaling as a novel mediator of proliferation in metastatic colorectal cancer cells. Taken together, our data support development of novel strategies to inhibit CDK1 and/or GR for the treatment of metastatic human colorectal cancers.

**Data Availability**

All the data collected and analyzed for this study can be found in the submitted results (Figures).
References

1. Jemal, A. et al. Global cancer statistics. *CA Cancer J Clin* **61**, 69–90, https://doi.org/10.3322/caac.20107 (2011).

2. Ogata-Kawara, H. et al. Circulating exosomal microRNAs as biomarkers of colon cancer. *PLoS One* **9**, e92921, https://doi.org/10.1371/journal.pone.0092921 (2014).

3. Chen, Y. et al. Survival of metastatic colorectal cancer patients treated with chemotherapy in Alberta (1995–2004). *Support Care Cancer* **18**, 217–224, https://doi.org/10.1007/s00520-009-0647-x (2010).

4. Brenner, H., Kloor, M. & Pox, C. P. Colorectal cancer. *Lancet* **383**, 1490–1502, doi:10.1016/S1666-3021(13)61649-9 (2014).

5. Garden, O. J. et al. Guidelines for resection of colorectal cancer liver metastases. * Gut* **55** (Suppl 3), iii–8, https://doi.org/10.1136/gut.2006.098053 (2006).

6. Simmonds, P. C. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. *BMJ* **321**, 531–535 (2000).

7. Simmonds, P. C. et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. *Br J Cancer* **94**, 982–999, https://doi.org/10.1038/sj.bjc.6603033 (2006).

8. Holt, L. J. et al. Global analysis of CdK1 substrate phosphorylation sites provides insights into evolution. *Science* **325**, 1682–1686, https://doi.org/10.1126/science.1172867 (2009).

9. Ravindran Menon, D. et al. CDK1 Interacts with Sox2 and Promotes Tumor Initiation in Human Melanoma. *Cancer Res* **78**, 6561–6574, https://doi.org/10.1158/0008-5472.CAN-18-0330 (2018).

10. Malumbres, M. & Barbacid, M. Cell cycle, CDKs and cancer: a changing paradigm. *Nat Rev Cancer* **9**, 153–166, https://doi.org/10.1038/nrc2602 (2009).

11. Wang, X. K. et al. Mono-(2-Ethylhexyl) Phthalate Promotes Pro-Labor Gene Expression in the Human Placenta. *PLoS One* **11**, e0147013, https://doi.org/10.1371/journal.pone.0147013 (2016).

12. Lee, D. E. & Dahiya, R. MethPrimer: designing primers for methylation PCRs. *Bioinformatics* **18**, 1427–1431, https://doi.org/10.1093/bioinformatics/18.11.1427 (2002).

13. Vermeulen, K., Van Bockstaele, D. R. & Berneman, Z. N. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. *Cell Prolif* **36**, 131–149 (2003).

14. Ding, L., Yu, L. L., Han, N. & Zhang, B. T. miR-141 promotes colon cancer cell proliferation by inhibiting MAP2K4. *Carcinogenesis* **32**, 629–635, https://doi.org/10.1093/carcin/bgr008 (2011).

15. Farhan, M. et al. Differential Methylation and Acetylation as the Epigenetic Basis of Resveratrol’s Anticancer Activity. *Medicines* (Basel)**6**, https://doi.org/10.3390/medicines6010024 (2019).

16. Daga-Jack, I. & Shaw, A. T. Tumour heterogeneity and resistance to cancer therapies. *Nat Rev Clin Oncol* **15**, 81–94, https://doi.org/10.1038/nrclinonc.2017.166 (2018).

17. Blank, A., Roberts, D. E. II, Dawson, H., Zlobec, I. & Lugli, A. Tumor Heterogeneity in Primary Colorectal Cancer and Corresponding Metastases. Does the Apple Fall Far From the Tree? *Front Med (Lausanne)* **5**, 234, https://doi.org/10.3389/fmed.2018.00234 (2018).

18. van der Pompe, G., Antoni, M. H. & Heijnen, C. J. Elevated basal cortisol levels and attenuated ACTH and cortisol responses to a behavioral challenge in women with metastatic breast cancer. *Psychooncology* **21**, 361–374 (1996).

19. Sephton, S. E., Sapolsky, R. M., Kraemer, H. C. & Spiegel, D. Diurnal cortisol rhythm as a predictor of breast cancer survival. *J Natl Cancer Inst* **92**, 994–1000 (2000).

20. Obradovic, M. M. S. et al. Glucocorticoids promote breast cancer metastasis. *Nature* **567**, 540–544, https://doi.org/10.1038/s41586-019-0109-4 (2019).

21. Eversink, J. M. & Kolodner, R. D. An overview of CdK1-targeted drugs and processes. *Cell Div* **5**, 9, https://doi.org/10.1186/s1778-0128-5-11 (2010).

22. Otto, T. & Scinscki, P. Cell cycle proteins as promising targets in cancer therapy. *Nat Rev Cancer* **17**, 91–115, https://doi.org/10.1038/nrc.2016.138 (2017).

23. Ortega, S., Malumbres, M. & Barbacid, M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. *Biochim Biophys Acta* **1602**, 73–87 (2002).

24. Zhang, P. et al. Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer. *Mol Cancer Res* **16**, 378–389, https://doi.org/10.1158/1541-7786.MCR-17-0048 (2018).

25. Cancer Genome Atlas, Atlas, N. Comprehensive molecular characterization of human colon and rectal cancer. *Nature* **487**, 330–337, https://doi.org/10.1038/nature11252 (2012).

Author Contributions

D.T. and G.H. performed experiments; D.T., M.T. and G.H. collected data; D.T., M.T. and J.-L.L. analyzed data; D.T. and M.T. prepared first draft; J.-L.L. finalized manuscript and submitted manuscript.

Additional Information

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019